BioSpace News Archive

Camino Pharma, LLC announced today that it has dosed the first cohort in a Phase 1 clinical trial of SBP-9330 in healthy subjects. SBP–9330 targets a neuronal signaling pathway underlying addictive behaviors and would be a first-in-class oral therapeutic to help people quit smoking.

Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ), today reported its financial results for the year ended February 28, 2021.

Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces that the Company will host an investor call during which Management will present the Interim Report First Half 2021.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences.

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9, 2021, at 8:45 a.m. ET.

Global health service company Cigna Corporation (NYSE:CI) announced today that David Cordani, president and chief executive officer, will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021 through a virtual webcast.

Novavax, Inc. (Nasdaq: NVAX), today announced that Novavax’ recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO, now underway in the UK to evaluate the safety and immunogenicity of a third COVID-19 vaccine dose in participants with impaired immune systems.

Parker Laboratories, Inc., announces three additions to its Helix™ line – Tri-Active Therapy Cream, Helix CBD Therapy Cream, and CBD Clinical Cream.

Focus of manufacturers on the development of novel devices such as wrist ABPM devices and various advanced monitors that can connect to mobile phones to detect high blood pressure would have a significant impact on the market growth.

Moderna, Inc. today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the full licensure of the Moderna COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older.